UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo AB (STO:ORX):
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2013.
Zubsolv® continues to gain market share
Fourth quarter 2014
· Total net revenues amounted to MSEK 220.5 (99.5). Revenues from launched products, excluding one-off milestones, amounted to MSEK 162.0 (99.5).
· Earnings after tax were MSEK 51.6 (-37.8).
Help employers find you! Check out all the jobs and post your resume.
